Thermo Fisher Scientific introduces the CE-IVD (IVDD) Oncomine Dx Express Test and Oncomine Reporter Dx for use in clinical labs. Using targeted NGS technology, the test delivers clinically relevant tumor mutation profiling in as little as 24 hours to aid health care professionals with therapy management of cancer patients. The qualitative in vitro diagnostic test detects deletions, insertions, substitutions, and copy number gain present in 42 genes and fusions or splicing variants in 18 genes from DNA and RNA in FFPE tumor tissue samples of solid malignant neoplasms. The assay also detects deletions, insertions, substitutions in 42 genes and fusions or splicing variants in seven genes from cfTNA extracted from plasma samples of non-small cell lung cancer (NSCLC). The software aims to allow quick access to genomic test results and matches the variant data to relevant evidence including approved therapies, guidelines, clinical trials, and peer reviewed literature in a customizable report.